Cited by 164MicroRNA in disease regulationGlioma Diagnosis and TreatmentCancer-related molecular mechanisms research

MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3)

Open access
Yang, Chuan He, Yue, Junming, Pfeffer, Susan R., Fan, Meiyun, Paulus, Elena, Hosni-Ahmed, Amira, Sims, Michelle, Qayyum, Sohail +3 more·2014·Journal of Biological Chemistry

Abstract

Despite advances in surgery, imaging, chemotherapy, and radiation, patients with glioblastoma multiforme (GBM), the most common histological subtype of glioma, have an especially dismal prognosis; >70% of GBM patients die within 2 years of diagnosis. In many human cancers, the microRNA miR-21 is overexpressed, and accumulating evidence indicates that it functions as an oncogene. Here, we report that miR-21 is overexpressed in human GBM cell lines and tumor tissue. Moreover, miR-21 expression in GBM patient samples is inversely correlated with patient survival. Knockdown of miR-21 in GBM cells inhibited cell proliferation in vitro and markedly inhibited tumor formation in vivo. A number of known miR-21 targets have been identified previously. By microarray analysis, we identified and validated insulin-like growth factor (IGF)-binding protein-3 (IGFBP3) as a novel miR-21 target gene. Overexpression of IGFBP3 in glioma cells inhibited cell proliferation in vitro and inhibited tumor formation of glioma xenografts in vivo. The critical role that IGFBP3 plays in miR-21-mediated actions was demonstrated by a rescue experiment, in which IGFBP3 knockdown in miR-21KD glioblastoma cells restored tumorigenesis. Examination of tumors from GBM patients showed that there was an inverse relationship between IGFBP3 and miR-21 expression and that increased IGFBP3 expression correlated with better patient survival. Our results identify IGFBP3 as a novel miR-21 target gene in glioblastoma and suggest that the oncogenic miRNA miR-21 down-regulates the expression of IGFBP3, which acts as a tumor suppressor in human glioblastoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m114.593863

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inhibition of miR-21 via different strategies elevated apoptotic cell death, sensitivity to chemotherapy/radiotherapy, and diminished tumor progression.

    “Inhibition of miR-21 via different strategies elevated apoptotic cell death, sensitivity to chemotherapy/radiotherapy, and diminished tumor progression (24–28).”

    From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [27]

    The Discussion (page unavailable) reports that miR-21 knockdown sensitized cells to the apoptotic effects of chemotherapeutic agents, and the paper reports that knockdown markedly inhibited tumor formation in vivo. It describes miR-21 as involved in resistance to radiation, but does not show that inhibition increased radiotherapy sensitivity; this study also uses an antagomiR-21 knockdown strategy rather than demonstrating different inhibition strategies. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • miR-21 silencing has demonstrated effective results both in vitro and in vivo.

    “In addition, miR-21 silencing has demonstrated effective results both in vitro and in vivo (24–28).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, R. L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negrini, M., Harris, C. C., and Croce, C. M. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257-2261
  2. Wen, S., Stolarov, J., Myers, M. P., Su, J. D., Wigler, M. H., Tonks, N. K., and Durden, D. L. (2001) PTEN controls tumor-induced angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 98, 4622-4627
  3. Trojan, J., Blossey, B. K., Johnson, T. R., Rudin, S. D., Tykocinski, M., Ilan, J., and Ilan, J. (1992) Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth fac- tor I. Proc. Natl. Acad. Sci. U.S.A. 89, 4874 -4878

Cited by

Sorted by citations

Authors
Yang, C. H., Yue, J., Pfeffer, S. R., Fan, M., Paulus, E., Hosni-Ahmed, A., Sims, M., Qayyum, S., Davidoff, A. M., Handorf, C. R., & Pfeffer, L. M.
Affiliations
  • University of Tennessee Health Science Center (US)
  • St. Jude Children's Research Hospital (US)
Corresponding author
Pfeffer, Lawrence M.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2014-09
Volume
289
Issue
36
Pages
25079-25087
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2033541023
Cited by
164
References
1
Citations by year
2026: 6 · 2025: 7 · 2024: 14 · 2023: 9 · 2022: 12 · 2021: 15 · 2020: 19 · 2019: 19 · 2018: 13 · 2017: 17 · 2016: 12 · 2015: 20 · 2014: 1
FWCI
5.34
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (CA133322, 21766)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
miR-21, glioblastoma, IGFBP-3, insulin-like growth factor binding protein-3, miRNA target genes, oncogenic microRNA, tumor suppressor, cell proliferation, carcinogenesis, patient survival, xenograft tumor formation
MeSH terms
Animals, Glioblastoma, Humans, Luciferases, Male, Mutation, Immunoblotting, Down-Regulation, Gene Expression Regulation, Neoplastic, Survival Analysis, Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Insulin-Like Growth Factor Binding Protein 3, Reverse Transcriptase Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, 3' Untranslated Regions, Gene Expression Profiling, Xenograft Model Antitumor Assays, MicroRNAs, Cell Line, Tumor, Interleukin Receptor Common gamma Subunit, Gene Knockdown Techniques, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review